 |
|
|
| |
Efficacy and Safety of Bulevirtide Monotherapy Given at 2 mg or 10 mg Dose Level Once Daily for Treatment of Chronic Hepatitis Delta: Week 48 Primary Endpoint Results From a Phase 3 Randomized, Multicenter, Parallel Design Study
|
| |
| |
EASL 2022 June 22-26 London
Heiner Wedemeyer,1 Soo Aleman,2 Maurizia Brunetto,3 Antje Blank,4 Pietro Andreone,5 Pavel Bogomolov,6
Vladimir Chulanov,7 Nina Mamonova,7 Natalia Geyvandova,8 Viacheslav Morozov,9 Olga Sagalova,10
Tatyana Stepanova,11 Dmitry Manuilov,12 Vithika Suri,12 Qi An,12 John F. Flaherty,12 Anu Osinusi,12
Julian Schulze zur Wiesch,13 Markus Cornberg,1 Stefan Zeuzem,14 Pietro Lampertico15,16
1Klinik fur Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Germany; 2Karolinska University Hospital/Karolinska Institutet, Stockholm, Sweden; 3University Hospital of Pisa and Dept of Clinical and Experimental Medicine, University of Pisa, Italy; 4Heidelberg University Hospital, Heidelberg, Germany; 5University of Modena and Reggio Emilia, Italy; 6M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; 7FSBI National Research Medical Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, Moscow, Russian Federation; 8Stavropol Regional Hospital, Stavropol, Russian Federation; 9LLC Medical Company "Hepatolog", Samara, Russian Federation; 10Southern Ural State Medical University, Chelyabinsk, Russian Federation; 11Clinic of Modern Medicine, Moscow, Russian Federation; 12Gilead Sciences, Inc., Foster City, California, USA; 13Universitätsklinikum Hamburg-Eppendorf Medizinische Klinik Studienambulanz Hepatologie, Hamburg, Germany; 14University Hospital Frankfurt, Frankfurt am Main, Germany; 15Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 16 "A.M. e A. Migliavacca" Center for the Study of Liver Disease, Universitā degli Studi di Milano, Italy
|
| |
|
|
|
|
|
